Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction

Chia Nan University of Pharmacy & Science Institutional Repository > 行政單位 > 123 > Item 310902800/34559

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34559

標題:	Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction
作者:	Chang, Wei-Ting Lin, Yu-Wen Chen, Chin-Yu Chen, Zhih-Cherng Shih, Jhih-Yuan Wu, Chia-Ching Luo, Chwan-Yau Liu, Ping-Yen
貢獻者:	National Cheng Kung University Chi Mei Hospital Southern Taiwan University of Science & Technology Chi Mei Hospital Chia Nan University of Pharmacy & Science National Cheng Kung University National Cheng Kung University National Cheng Kung University National Cheng Kung University National Cheng Kung University Hospital Kaohsiung Medical University National Cheng Kung University National Cheng Kung University Hospital
關鍵字:	heart-failure oxidative stress spironolactone fibrosis disease
日期:	2022
上傳時間:	2023-12-11 13:57:50 (UTC+8)
出版者:	MDPI
摘要:	Mitral regurgitation (MR), the disruption of the mitral valve, contributes to heart failure (HF). Under conditions of volume overload, excess mineralocorticoids promote cardiac fibrosis. The mineralocorticoid receptor antagonist spironolactone is a potassium-sparing diuretic and a guideline-recommended therapy for HF, but whether it can ameliorate degenerative MR remains unknown. Herein, we investigate the efficacy of spironolactone in improving cardiac remodeling in MR-induced HF compared with that of a loop diuretic, furosemide. Using a novel and mini-invasive technique, we established a rat model of MR. We treated the rats with spironolactone or furosemide for twelve weeks. The levels of cardiac fibrosis, apoptosis, and stress-associated proteins were then measured. In parallel, we compared the cardiac remodeling of 165 patients with degenerative MR receiving either spironolactone or furosemide. Echocardiography was performed at baseline and at six months. In MR rats treated with spironolactone, left ventricular function-especially when strained-and the pressure volume relationship significantly improved compared to those of rats treated with furosemide. Spironolactone treatment demonstrated significant attenuation of cardiac fibrosis and apoptosis in left ventricular tissue compared to furosemide. Further, spironolactone suppressed the expression of apoptosis-, NADPH oxidase 4 (NOX4)- and inducible nitric oxide synthase (iNOS)-associated proteins. Similarly, compared with MR patients receiving furosemide those prescribed spironolactone demonstrated a trend toward reduction in MR severity and showed improvement in left ventricular function. Collectively, MR-induced cardiovascular dysfunction, including fibrosis and apoptosis, was effectively attenuated by spironolactone treatment. Our findings suggest a potential therapeutic option for degenerative MR-induced HF.
關聯:	CELLS, v.11, n.CB2, pp.CC2, pp.-1880,
顯示於類別:	[行政單位] 123

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	84	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....